Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€103.46

€103.46

1.080%
1.1
1.080%
€109.00
 
27.09.24 / Tradegate WKN: 920657 / Name: Snof / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Sanofi S.A. Stock

There is an upward development for Sanofi S.A. compared to yesterday, with an increase of €1.10 (1.080%).
Currently there is a rather positive sentiment for Sanofi S.A. with 4 Buy predictions and 0 Sell predictions.
With a target price of 109 € there is a slightly positive potential of 5.35% for Sanofi S.A. compared to the current price of 103.46 €.
So far the community has only identified positive things for Sanofi S.A. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Sanofi S.A. in the next few years

Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Sanofi S.A. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sanofi S.A. 1.080% 0.213% 2.904% 2.355% 15.276% 25.757% 22.612%
Ipsen S.A. -0.630% -0.626% 3.541% -9.232% 3.638% 33.823% 26.971%
Elanco Animal Health Inc. 4.060% 1.762% -1.339% 19.182% -5.148% -54.298% -
Johnson & Johnson 0.470% -1.646% -0.769% -3.356% 2.105% 3.656% 23.005%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financials of Snof, a notable player in the pharmaceuticals industry under the US symbol, reveal a company that is navigating the complexities of the market with a significant degree of stability. At first glance, the metrics suggest that Snof is maintaining a solid financial position, showcasing steady revenue growth and robust earnings, while also investing heavily in research and development. However, a deeper dive into specific figures illustrates both strengths and weaknesses that can help shape expectations for potential investors or stakeholders.

Strong Revenue Generation: For the fiscal year ending December 31, 2023, Snof reported total revenues of approximately €43.07 billion. This sizable revenue indicates robust demand for its pharmaceutical products and the effectiveness of its sales strategy, especially considering the revenue reflected a continued upward trend from previous years.

Solid Profit Margins: The profit margin stands at approximately 8.95%, which suggests that Snof is not only generating revenue but also retaining a healthy portion as profit. This profitability is further emphasized by a stable operating margin of 14.11%, making it clear that operational efficiency is being managed well.

Comments

Prediction Buy
Perf. (%) 1.76%
Target price 95.000
Change
Ends at 06.02.23

Buy with target price 95.0
Show more

Prediction Buy
Perf. (%) 20.12%
Target price 89.000
Change
Ends at 14.09.22

Buy with target price 89.0
Show more

Prediction Sell
Perf. (%) 9.12%
Target price
Change
Ends at 20.12.19

Sell beendet
Show more